GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » LivaNova PLC (NAS:LIVN) » Definitions » YoY EPS Growth

LivaNova (LivaNova) YoY EPS Growth : 900.00% (As of Dec. 2023)


View and export this data going back to 1993. Start your Free Trial

What is LivaNova YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. LivaNova's YoY EPS Growth for the quarter that ended in Dec. 2023 was 900.00%.

LivaNova's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $0.30.


LivaNova YoY EPS Growth Historical Data

The historical data trend for LivaNova's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LivaNova YoY EPS Growth Chart

LivaNova Annual Data
Trend Apr14 Apr15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.62 -120.25 62.67 39.93 119.88

LivaNova Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 130.00 133.33 -93.33 93.03 900.00

LivaNova YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

LivaNova's YoY EPS Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EPS Growth (A: Dec. 2023 )
=(Earnings per Share (Diluted) (A: Dec. 2023 )-Earnings per Share (Diluted) (A: Dec. 2022 ))/ | Earnings per Share (Diluted) (A: Dec. 2022 ) |
=(0.32--1.61)/ | -1.61 |
=119.88 %

LivaNova's YoY EPS Growth for the quarter that ended in Dec. 2023 is calculated as:

YoY EPS Growth (Q: Dec. 2023 )
=(Earnings per Share (Diluted) (Q: Dec. 2023 )-Earnings per Share (Diluted) (Q: Dec. 2022 )) / | Earnings per Share (Diluted) (Q: Dec. 2022 )) |
=(0.3-0.03)/ | 0.03 |
=900.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


LivaNova YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of LivaNova's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


LivaNova (LivaNova) Business Description

Traded in Other Exchanges
Address
20 Eastbourne Terrace, London, GBR, W2 6LG
U.K.-based LivaNova was born of a combination between Cyberonics in the U.S. and Sorin in Italy. The medical device firm is primarily focused on cardiovascular and cardiopulmonary solutions (with surgical heart valves, heart-lung machines, and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management and heart valve businesses. LivaNova derives roughly half of its revenue from the U.S. market, another 21% from Europe, and the remainder from the rest of the world.
Executives
James Christopher Barry director 7475 LUSK BLVD, SAN DIEGO CA 92121
Damien Mcdonald officer: COO 5 MERCHANT SQUARE, NORTH WHARF ROAD, LONDON X0 W21AY
Michael Damon Hutchinson officer: Chief Legal Officer 2825 AIRVIEW BLVD, KALAMAZOO MI 49002
Brooke Story director C/O SIGILON THERAPEUTICS, INC., 100 BINNEY STREET, SUITE 600, CAMBRIDGE MA 02142
Peter M Wilver director
Daniel Jeffrey Moore director 100 CYBERONICS BVLD, HOUSTON TX 77058
Alfred J Novak director 325 NE 6TH ST, BOCA RATON FL 33432
William A Kozy director C/O BECTON DICKERSON & CO, 1 BECTON DR, FRANKLIN LAKES NJ 07417
Marco Dolci officer: SVP Global Operations, R&D VIA BENIGNO CRESPI 17, MILAN L6 20159
Todd C Schermerhorn director C/O C.R BARD INC, 730 CENTRAL AVE, MURRAY HILL NJ 07974
Alex Shvartsburg officer: Interim CFO 20 EASTBOURNE TERRACE, LONDON X0 W26LG
Roy Khoury officer: President, International 5 MERCHANT SQUARE, NORTH WHARF ROAD, LONDON X0 W21AY
Thad Allen Huston officer: Chief Financial Officer 941 BLOOMFIELD ST, HOBOKEN NJ 07030
Seng Stacy Enxing director C/O HILL-ROM HOLDINGS, INC., SUITE 4100 180 NORTH STETSON AVENUE, CHICAGO IL 60601
Trui Hebbelinck officer: Chief Human Resources Officer 20 EASTBOURNE TERRACE, LONDON X0 W2 6LG

LivaNova (LivaNova) Headlines

From GuruFocus

LivaNova to Announce Third-Quarter 2023 Results

By Business Wire 09-20-2023

LivaNova Reports Second-Quarter 2023 Results

By Business Wire 07-26-2023

LivaNova to Announce First-Quarter 2023 Results

By Business Wire Business Wire 03-22-2023

LivaNova to Announce Fourth-Quarter and Full-Year 2022 Results

By Business Wire Business Wire 01-18-2023

LivaNova to Announce First-Quarter 2022 Results

By Business Wire Business Wire 03-24-2022

LivaNova Launches SenTiva DUO

By Business Wire Business Wire 02-03-2023